ABOUT TOUCHLIGHT
Touchlight is an innovation-driven leading CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. As pioneers, with an FDA Drug Master File accepted in 2022 followed in 2025 with the world’s first cell-free DNA GMP license, Touchlight’s enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and gene editing technology with its state-of-the-art facility recognised by ISPE’s Facility of the Year Awards (FOYA) for Innovation.
With multiple client products already in the clinic, Touchlight’s evidence-based, synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. The company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, Touchlight’s team is inspired by breakthroughs in genetic medicine, recognising the urgent need for innovative DNA production techniques to support the future of genetic therapies.
INDUSTRY INSIGHTS
-
![Viral vector, gene therapy, DNA delivery-GettyImages-2193840525]( "Enhancing AAV Production Performance And Economics")
Enhancing AAV Production Performance And EconomicsEnzymatically produced dbDNA offers safer, faster, and more scalable AAV manufacturing by reducing costs, improving full capsid yields, and enabling high‑fidelity, bacteria‑free DNA production.
-
![GettyImages-481911027-mrna-3d-structure-dna-helix]( "Enzymatic Circular DNA For Next‑Gen Gene Editing")
Enzymatic Circular DNA For Next‑Gen Gene EditingNext‑gen circular DNA payloads enhance gene insertion by improving stability, lowering cytotoxicity, and enabling precise, scalable integration across HDR, recombination, and transposition systems.
-
![GettyImages-2138730502-dna-with-grass-and-flowers]( "mbDNA™: The Smarter DNA For Non-Viral Gene Editing")
mbDNA™: The Smarter DNA For Non-Viral Gene EditingA next‑gen single‑stranded DNA template improves non‑viral gene editing by boosting viability, knock‑in efficiency, delivery flexibility, and stability while overcoming limits of viral vectors.
-
![GettyImages-2196603030 lab, research, gene therapy]( "Unlocking AAV Gene Therapy Cost Of Goods Savings")
Unlocking AAV Gene Therapy Cost Of Goods SavingsComparing plasmid DNA to enzymatically produced DNA shows how enzymatic methods cut manufacturing costs, speed production, and boost efficiency for large‑scale AAV gene therapy.
CONTACT INFORMATION
Touchlight
Lower Sunbury Road
Hampton, TW12 2ER
UNITED KINGDOM
Phone: +442084819200
SOLUTIONS
-
![Gene editing, gene therapy-GettyImages-930103248]( "mbDNA™ And Custom Circles In Gene Editing")
Engineered circular DNA formats enabling efficient, low‑toxicity gene editing with high stability, customizable architectures, reduced immune activation, and broad applicability.
